GB
Therapeutic Areas
BrYet Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ML-016 (iNPG-pDox) | Lung and Liver Metastases | Phase 1/2 |
Leadership Team at BrYet
MF
Mauro Ferrari, PhD
President, CEO, and Board Chair
BS
Brian Sapp
Chief Technology Officer
MW
Matt Wagener
Director of Clinical Operations
LP
Lorenzo Pradella
Chief Executive Officer, BrYet Europe
DC
Dawn Cox
Chief Administrative Officer
CC
Christopher Cano, MBA
Director of Business Development